Drug Trial Radar · NCT00111163
Intermittent Preventive Treatment With Antimalarials in Kenyan Infants
Last checked: Nov 19, 2026Latest source record: Sep 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,516
Actual
Start
Mar 2004
Primary completion
Mar 2006
Study completion Mar 2008
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Kenya Medical Research Institute; Bill and Melinda Gates Foundation
- First posted
- May 18, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 5 weeks, up to 16 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to see whether antimalarial drugs administered at the time of routine infant vaccinations prevents malaria and anemia in the first year of life.
Conditions
- Malaria
- Anemia
Interventions
sulfadoxine-pyrimethamine with artesunateDrug
amodiaquine with artesunateDrug
chlorproguanil-dapsoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical malaria in the first year of life
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lwak, Abidha, Ongielo and Saradidi clinics
Asembo (Rarieda Division), Nyanza Province, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.